327 related articles for article (PubMed ID: 31090936)
41. Is There Still a Role for Low-Dose All-Transretinoic Acid in the Treatment of Acute Promyelocytic Leukemia in the Arsenic Trioxide Era?
Jaime-Pérez JC; González-Leal XJ; Pinzón-Uresti MA; Gómez-De León A; Cantú-Rodríguez OG; Gutiérrez-Aguirre H; Gómez-Almaguer D
Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):816-9. PubMed ID: 26500134
[TBL] [Abstract][Full Text] [Related]
42. Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy.
Coutre SE; Othus M; Powell B; Willman CL; Stock W; Paietta E; Levitan D; Wetzler M; Attar EC; Altman JK; Gore SD; Maher T; Kopecky KJ; Tallman MS; Larson RA; Appelbaum FR
Br J Haematol; 2014 May; 165(4):497-503. PubMed ID: 24528179
[TBL] [Abstract][Full Text] [Related]
43. Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia: the APL92 study of the Japan Adult Leukemia Study Group (JALSG).
Asou N; Adachi K; Tamura U; Kanamaru A; Kageyama S; Hiraoka A; Omoto E; Akiyama H; Tsubaki K; Saito K; Kuriyama K; Oh H; Kitano K; Miyawaki S; Takeyama U; Yamada O; Nishikawa K; Takahashi M; Matsuda S; Ohtake H; Ohno R
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S65-71. PubMed ID: 11587370
[TBL] [Abstract][Full Text] [Related]
44. A prospective, observational study of added medium-dose cytosine arabinoside versus As2O3 for elderly patients with acute promyelocytic leukemia.
Huang BT; Zeng QC; Zhao WH; Li BS; Chen RL
Med Oncol; 2014 Oct; 31(10):233. PubMed ID: 25213763
[TBL] [Abstract][Full Text] [Related]
45. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group.
Asou N; Adachi K; Tamura J; Kanamaru A; Kageyama S; Hiraoka A; Omoto E; Akiyama H; Tsubaki K; Saito K; Kuriyama K; Oh H; Kitano K; Miyawaki S; Takeyama K; Yamada O; Nishikawa K; Takahashi M; Matsuda S; Ohtake S; Suzushima H; Emi N; Ohno R
J Clin Oncol; 1998 Jan; 16(1):78-85. PubMed ID: 9440726
[TBL] [Abstract][Full Text] [Related]
46. Safety and efficacy of arsenic trioxide and all-trans retinoic acid therapy in acute promyelocytic leukemia patients with a high risk for early death.
Min GJ; Cho BS; Park SS; Park S; Jeon YW; Yahng SA; Shin SH; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim HJ
Ann Hematol; 2020 May; 99(5):973-982. PubMed ID: 32270215
[TBL] [Abstract][Full Text] [Related]
47. Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy.
Cicconi L; Breccia M; Franceschini L; Latagliata R; Molica M; Divona M; Diverio D; Rizzo M; Ottone T; Iaccarino L; Alfonso V; Foa R; Voso MT; Lo-Coco F
Ann Hematol; 2018 Oct; 97(10):1797-1802. PubMed ID: 29951912
[TBL] [Abstract][Full Text] [Related]
48. Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy.
Lou Y; Suo S; Tong H; Ye X; Wang Y; Chen Z; Qian W; Meng H; Mai W; Huang J; Tong Y; Jin J
Leuk Res; 2013 Nov; 37(11):1451-6. PubMed ID: 23958062
[TBL] [Abstract][Full Text] [Related]
49. All-trans-retinoic acid in acute promyelocytic leukemia.
Tallman MS; Andersen JW; Schiffer CA; Appelbaum FR; Feusner JH; Ogden A; Shepherd L; Willman C; Bloomfield CD; Rowe JM; Wiernik PH
N Engl J Med; 1997 Oct; 337(15):1021-8. PubMed ID: 9321529
[TBL] [Abstract][Full Text] [Related]
50. Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance).
Kutny MA; Geyer S; Laumann KM; Gregory J; Willman CL; Stock W; Larson RA; Powell BL; Feusner JH
Pediatr Blood Cancer; 2019 Mar; 66(3):e27542. PubMed ID: 30393935
[TBL] [Abstract][Full Text] [Related]
51. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
[TBL] [Abstract][Full Text] [Related]
52. Long-term retrospective study of retinoic acid combined with arsenic and chemotherapy for acute promyelocytic leukemia.
Zhang X; Wu S; Yang J; Zhang G; Su Y; Zhang M; He J; Shi Y; Li W; Lu P; Lu D
Int J Hematol; 2023 Apr; 117(4):530-537. PubMed ID: 36580227
[TBL] [Abstract][Full Text] [Related]
53. Long-term effect of all-trans retinoic acid and arsenic trioxide sequential maintenance in patients with acute promyelocytic leukemia.
Tao S; Wang C; Chen Y; Deng Y; Song L; Shi Y; Ling L; Ding B; He Z; Yu L
Leuk Lymphoma; 2019 Mar; 60(3):711-719. PubMed ID: 30407095
[TBL] [Abstract][Full Text] [Related]
54. Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia.
Zhang Y; Wu S; Luo D; Zhou J; Li D
PLoS One; 2016; 11(1):e0147545. PubMed ID: 26812490
[TBL] [Abstract][Full Text] [Related]
55. Long term curative effects of sequential therapy with all-trans retinoic acid, arsenious oxide and chemotherapy on patients with acute promyelocytic leukemia.
Pei R; Cao J; Ma J; Zhang P; Liu X; Du X; Chen D; Sha K; Chen L; Li S; Wu J; Fan Z; Lin L; Ye P; Tang S; Zhang B
Hematology; 2012 Nov; 17(6):311-6. PubMed ID: 23168069
[TBL] [Abstract][Full Text] [Related]
56. Combination therapy with arsenic trioxide, all-trans retinoic acid, and chemotherapy in acute promyelocytic leukemia patients with various relapse risks.
Huang H; Qin Y; Xu R; You X; Teng R; Yang L; Xu M; Liu H
Leuk Res; 2012 Jul; 36(7):841-5. PubMed ID: 22534100
[TBL] [Abstract][Full Text] [Related]
57. All-trans retinoic acid therapy for newly diagnosed acute promyelocytic leukemia: comparison with intensive chemotherapy. The Japan Adult Leukemia Study Group (JALSG).
Asou N; Adachi K; Tamura J; Kanamaru A; Kageyama S; Hiraoka A; Omoto E; Sakamaki H; Tsubaki K; Saito K; Ohno R
Cancer Chemother Pharmacol; 1997; 40 Suppl():S30-5. PubMed ID: 9272131
[TBL] [Abstract][Full Text] [Related]
58. Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia.
Park YH; Kim DY; Mun YC; Cho EK; Lee JH; Jo DY; Kim I; Yoon SS; Park SY; Kim B; Bang SM; Kim H; Min YJ; Park JH; Seo JJ; Moon HN; Lee MH; Kim CS; Lee WS; Chong SY; Oh D; Zang DY; Lee KH; Hyun MS; Kim HS; Kim SH; Kwon H; Kim HJ; Park KT; Bae SH; Ryoo HM; Choi JH; Ahn MJ; Yoon HJ; Nam SH; Kim BS; Seong CM
Korean J Intern Med; 2022 Jul; 37(4):841-850. PubMed ID: 35811370
[TBL] [Abstract][Full Text] [Related]
59. Treatment of relapsed acute promyelocytic leukemia by arsenic trioxide in Iran.
Alimoghaddam K; Ghavamzadeh A; Jahani M; Mousavi A; Iravani M; Rostami S; Ghaffari H; Hosseini R; Jalili M
Arch Iran Med; 2011 May; 14(3):167-9. PubMed ID: 21529103
[TBL] [Abstract][Full Text] [Related]
60. All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study.
Frankel SR; Eardley A; Heller G; Berman E; Miller WH; Dmitrovsky E; Warrell RP
Ann Intern Med; 1994 Feb; 120(4):278-86. PubMed ID: 8291820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
